Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 52, 2009, Pages 22199-22204

  Dhar, Shanta ^a   Lippard, Stephen J ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cancer therapy; DNA damage; Mitochondrion; Platinum; Warburg effect

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CELL NUCLEUS DNA; CISPLATIN; CISPLATIN DERIVATIVE; CYTOCHROME C; DICHLOROACETIC ACID; MILTAPLATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; CROSS LINKING; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DICHLOROACETATE; DNA ADDUCTS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MOLECULAR STRUCTURE; ORGANOPLATINUM COMPOUNDS; ORPHAN DRUG PRODUCTION;

EID: 76049084604     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0912276106     Document Type: Article

References (40)

1. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891-899.
2. Warburg O (1956) On the origin of cancer cells. Science 123:309-314.
3. Samudio I, Fiegl M, Andreeff M (2009) Mitochondrial uncoupling and the Warburg effect: Molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 69:2163-2166.
4. Larsson N-G, Luft R (1999) Revolution in mitochondrial medicine. FEBS Lett 455:199-202.
5. Schon EA, DiMauro S (2003) Medicinal and genetic approaches to the treatment of mitochondrial disease. Curr Med Chem 10:2523-2533.
6. Don AS, Hogg PJ (2004) Mitochondria as cancer drug targets. Trends Mol Med 10:372-378.
7. Spierings D, et al. (2005) Connected to death: The (unexpurgated) mitochondrial pathway of apoptosis. Science 310:66-67.
8. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
9. Kim J-W, Dang CV (2006) Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66:8927-8930.
10. Xu R-h, et al. (2005) Inhibition of glycolysis in cancer cells:Anovel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65:613-621.
11. Stacpoole PW, et al. (2006) Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 117:1519-1531.
12. Stacpoole PW, Nagaraja NV, Hutson AD (2003) Efficacy of dichloroacetate as a lactatelowering drug. J Clin Pharmacol 43:683-691.
13. Bonnet S, et al. (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37-51.
14. StacpoolePW(1989)Thepharmacologyof dichloroacetate.MetabClinExp38: 1124-1144.
15. Pearson H (2007) Cancer patients opt for unapproved drug. Nature 446:474-475.
16. Cairns RA, Papandreou I, Sutphin PD, Denko NC (2007) Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci USA 104:9445-9450.
17. Cao W, et al. (2008) Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 68:1223-1231.
18. Wong JYY, Huggins GS, Debidda M, Munshi NC, De Vivo I (2008) Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 109:394-402.
19. Galanski M, Jakupec MA, Keppler BK (2005) Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches. Curr Med Chem 12:2075-2094.
20. Rosenberg B, VanCamp L, Trosko JE, Mansour VH (1969) Platinum compounds: A new class of potent antitumor agents. Nature 222:385-386.
21. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discovery 4:307-320.
22. Siddik ZH (2003) Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279.
23. Perego P, et al. (1996) Association between cisplatin resistance and mutation of p53 gene and reduced Bax expression in ovarian carcinoma cell systems. Cancer Res 56:556-562.
24. Giandomenico CM, et al. (2002) Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entree into orally active platinum(IV) antitumor agents. Inorg Chem 34:1015-1021.
25. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105:17356-17361.
26. Dhar S, Liu Z, Thomale J, Dai H, Lippard SJ (2008) Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J AmChem Soc 130:11467-11476.
27. Mukhopadhyay S, et al. (2008) Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjugate Chem 19:39-49.
28. Choy H, Park C,YaoM(2008) Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 14:1633-1638.
29. Choi S, et al. (1998) Reduction and anticancer activity of platinum(IV) complexes. Inorg Chem 37:2500-2504.
30. Cossarizza A, Baccaranai-Contri M, Kalashnikova G, Franceschi C (1993) A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′- tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun 197:40-45.
31. Floryk D, Houštěk J (1999) Tetramethyl rhodamine methyl ester (TMRM) is suitable for cytofluorometric measurements of mitochondrial membrane potential in cells treated with digitonin. Biosci Rep 19:27-34.
32. Jiang X, Wang X (2004) Cytochrome C-mediated apoptosis. Annu Rev Biochem 73:87-106.
33. Joza N, et al. (2001) Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 410:549-554.
34. Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467-2498.
35. Liedert B, Pluim D, Schellens J, Thomale J (2006) Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 34:e47.
36. Park SY, et al. (2004) Resistance of mitochondrial DNA-depleted cells against cell death: Role of mitochondrial superoxide dismutase. J Biol Chem 279:7512-7520.
37. Cullen KJ, Yang Z, Schumaker L, Guo Z (2007) Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 39:43-50.
38. Harper M-E, et al. (2002) Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J 16:1550-1557.
39. 2]. Indian J Chem 8:193-194.
40. Hall MD, et al. (2003) The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumor complexes in cancer cells. J Biol Inorg Chem 8:726-732.